Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes

Eur J Haematol. 2019 May;102(5):442-443. doi: 10.1111/ejh.13222. Epub 2019 Mar 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Transfusion
  • Deferasirox / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Iron Chelating Agents / therapeutic use*
  • Iron Overload / drug therapy*
  • Iron Overload / etiology*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / complications*
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Iron Chelating Agents
  • Deferasirox